The content on this site is intended for healthcare professionals only
Joyce O’Shaughnessy, MD, Baylor-Charles A. Sammons Cancer Center, Dallas, Texas, speaking at ASCO 2009: PARP Inhibitor BS-201 Plus Chemotherapy May Offer New Treatment Option for Triple-Negative Breast Cancer: A randomized Phase II study, featured in ASCO’s plenary session, shows that women with metastatic triple-negative breast cancer who received the investigational PARP inhibitor BSI-201, in combination with conventional chemotherapy, lived significantly longer and experienced significantly better progression-free survival than women who received standard chemotherapy alone.
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer
EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer
Comment: EBCC 2024 highlights
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer
CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer
